DOBUTAMINE

Indication	To increase conding and	ut in aba-	k ototoc						
indication	To increase cardiac output in shock states 2.5-10microgram/kg/minute								
	(Dose range 0.5–40 micrograms/kg/minute has been used)								
Door	,	•	-		•				
Dose	Start at an initial rate of 2 2.5microgram/kg/minute dose adjustments.								
	Each 50ml vial contains 250mg dobutamine (5mg/ml)								
	For peripheral use: 500mg in 250mls 2 milligrams per ml: max concentration peripherally								
Preparation	 Withdraw 100mls fluid from a 250ml bag of 0.9% sodium chloride or 5% glucose. Draw up 100mls of dobutamine (250mg in 50mls) and add 								
	 to bag. Label bag with contents, date of preparation and initials of staff preparing and checking infusion. 								
	FOR CENTRAL USE ONLY: Draw up 250mg (50ml) of Dobutamine into a 50ml syringe								
	Standard strength solutions may be given via peripheral or central line using the Baxter pump.								
A duninintuntion	central line using the baxter pump.								
Administration	High Strength solutions must only be infused via a central line.								
	When stopping infusion, reduce the rate gradually.								
Shelf-life	24 hours at room temperature								
	Contact the ward or oncall Pharmacist if unsure of the								
	calculations								
Additional	Glucose 5% can be used as a diluent if hypernatraemia is a								
information	problem								
	Tachycardia is the most common adverse reaction								
	DRUGS AD	WARD							
	A. Patient (A. Number	сси							
	DRUG	CHECK							
	DRUG Dobutamine AMOUNT 500mg ADDED BY				BY				
Sample Label									
	In 250ml sodíum chlor 0.9%/glucose 5%								
	DATE ADDED TIME ADDED	EXP. DATE EXP. TIME			BATCH No.				
	DISCONTINUE IF CL								

Dobutamine Dose Checker (Only for use with 2mg per ml Infusions)

All rates are in ml per hour.

Ideal Body Weight (kg)	Dose of dobutamine in micrograms per kg per minute											
	Increasing inotropic effect →											
	2.5	5	7.5	10	12.5	15	17.5	20	22.5	25	27.5	30
	All rates below in ml per hour (Only valid for 2mg/ml solutions)											
45	3.4	6.8	10.1	13.5	16.9	20.3	23.6	27.0	30.4	33.8	37.1	40.5
50	3.8	7.5	11.3	15.0	18.8	22.5	26.3	30.0	33.8	37.5	41.3	45.0
55	4.1	8.3	12.4	16.5	20.6	24.8	28.9	33.0	37.1	41.3	45.4	49.5
60	4.5	9.0	13.5	18.0	22.5	27.0	31.5	36.0	40.5	45.0	49.5	54.0
65	4.9	9.8	14.6	19.5	24.4	29.3	34.1	39.0	43.9	48.8	53.6	58.5
70	5.3	10.5	15.8	21.0	26.3	31.5	36.8	42.0	47.3	52.5	57.8	63.0
75	5.6	11.3	16.9	22.5	28.1	33.8	39.4	45.0	50.6	56.3	61.9	67.5
80	6.0	12.0	18.0	24.0	30.0	36.0	42.0	48.0	54.0	60.0	66.0	72.0
85	6.4	12.8	19.1	25.5	31.9	38.3	44.6	51.0	57.4	63.8	70.1	76.5
90	6.8	13.5	20.3	27.0	33.8	40.5	47.3	54.0	60.8	67.5	74.3	81.0
95	7.1	14.3	21.4	28.5	35.6	42.8	49.9	57.0	64.1	71.3	78.4	85.5
100	7.5	15.0	22.5	30.0	37.5	45.0	52.5	60.0	67.5	75.0	82.5	90.0
105	7.9	15.8	23.6	31.5	39.4	47.3	55.1	63.0	70.9	78.8	86.6	94.5
110	8.3	16.5	24.8	33.0	41.3	49.5	57.8	66.0	74.3	82.5	90.8	99.0

Written by Dominic Moore (Advanced Pharmacist –Specialist Medicine) August 2016 Updated by: Dominic Moore (Lead Pharmacist – Commissioning) June 2018 Reviewed by: Hester Smail (Advanced Pharmacist - Cardiology) November 2023 Approved by Dr Damian Kelly – Lead Cardiologist

Medical Division 15/3/19

For review November 2026

References

SmPC. http://www.emc.medicines.org.uk. Accessed November 2023 ASHP Injectable Drug Information. Accessed November 2023 UKCPA Minimum infusion volumes document. 4th edition. December 2012